Erika P. Hamilton, Michelino De Laurentiis, Komal L. Jhaveri, Xichun Hu, Sylvain Ladoire, Anne Patsouris, Claudio Zamagni, Jiuwei Cui, Marina Cazzaniga, Timuçin Çil, Katarzyna Joanna Jerzak, Christian Sebastian Fuentes, Tetsuhiro Yoshinami, Alvaro Rodriguez-Lescure, Olga Valota, Dongrui R. Lu, Marcella Martignoni, Janaki Parameswaran, Xin Zhi, Mario Campone. "Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.17_suppl.lba1000